Work

A Phase I Trial of Escalating Dose of the Rapamycin Analog Everolimus in Combination with the Kinase Inhibitor Midostaurin in Patients (pts) with Relapsed, Refractory or Poor Prognosis Acute Myeloid Leukemia (AML)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.3627.3627

Authors: Richard M. Stone, Caitlin Driscoll, Ilene Galinsky, Martha Wadleigh, David P. Steensma, David Avigan, Philip C. Amrein, Suiyang Liu, James D. Griffin, Steven L. McAfee, Eyal C. Attar, Karen K. Ballen, Edward Fox, Daniel J. DeAngelo

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979620775

FWCI:

Cites:

Cited by: 4

Related to: 10